POSITRON CORP
Positron is a medical technology company that develops, co-manufactures, sells and services PET and PET-CT imaging systems for nuclear cardiologists and other healthcare providers, including hospitals, outpatient imaging centers and physician practices. Its portfolio includes a dedicated PET system and the Affinity PET-CT platform, with applications in cardiology, oncology and neurology. The company also provides clinical and technical support, training, remote diagnostics, maintenance and software updates. Positron makes money through imaging system sales and related services, including rental and service agreements generally structured as multi-year contracts. Substantially all historical revenues have been derived from PET system services. Its systems are co-manufactured with Neusoft Medical Systems, and Positron also performs activities such as system configuration and testing. Positron is headquartered in North Tonawanda, New York.
No SEC Form 4 filings for $POSC in the last 30 days.
See all $POSC insider activity →Positron reported 3Q 2026 revenue of $102.67K, down 7.5% YoY, with net loss narrowing 6.9% to $971.98K. EPS remained at ($0.03). Service costs rose 34.0%, while G&A expenses fell 29.6%. The company plans to expand in nuclear cardiology and oncology. Cash position was $1.9M with $2.0M credit available.
Positron Corp (POSC) raised $2.0M via three 20% notes: $1.5M from George Ortiz, $400K from TISU Investments, and $100K from a third party. Notes mature in 2027, with interim interest payments. Positron also issued warrants for 400K shares and received $450K from Ortiz's warrant exercise.
POSITRON CORP (POSC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 30, 2026, Positron Corporation (the "Company") issued three unsecured promissory notes in the aggregate principal amount of $2,000,000 (collectively, the “Notes”). One Note in the amount of $1,500,000 was issued t
Over the past 7 days, AlphAI's AI scored 1 news story mentioning POSC (POSITRON CORP). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent POSC coverage spans corporate actions, financial news and earnings.
The revenue decline and modest loss narrowing suggest limited upside; investors may view the results as a negative catalyst.
The small, high‑interest raise adds modest liquidity but dilutes existing shareholders; limited price impact expected.
New high‑interest debt and warrant dilution increase financial risk and could pressure the share price.
The financing terms add near-term liquidity but introduce dilution risk via warrants and potential warrant repricing on default.
The sale of NeuSight PET-CT scanner signifies expansion in Positron's market presence, potentially boosting revenue and investor confidence.
AlphAI scores every news story that mentions POSC with an AI model for sentiment and relevance, and aggregates insider trades from POSITRON CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
Positron reported 3Q 2026 revenue of $102.67K, down 7.5% YoY, with net loss narrowing 6.9% to $971.98K. EPS remained at ($0.03). Service costs rose 34.0%, while G&A expenses fell 29.6%. The company plans to expand in nuclear cardiology and oncology. Cash position was $1.9M with $2.0M credit available.
Positron Corp (POSC) raised $2.0M via three 20% notes: $1.5M from George Ortiz, $400K from TISU Investments, and $100K from a third party. Notes mature in 2027, with interim interest payments. Positron also issued warrants for 400K shares and received $450K from Ortiz's warrant exercise.
POSITRON CORP (POSC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On September 30, 2026, Positron Corporation (the "Company") issued three unsecured promissory notes in the aggregate principal amount of $2,000,000 (collectively, the “Notes”). One Note in the amount of $1,500,000 was issued t
POSITRON CORP (POSC) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into Material Definitive Agreement. On August 13, 2026, Positron Corporation (the "Company") entered into a Line of Credit Agreement (the "Agreement") with George Ortiz ("Mr. Ortiz"), an existing, affiliated investor of the Company. Pursuant to the Agreement, Mr.
Niagara Falls, NY, May 29, 2025 ( GLOBE NEWSWIRE ) -- Positron Corporation ( "Positron" or the "Company" ) ( OTC: POSC ) , a leader in molecular imaging systems and services, is pleased to announce the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing ...
Niagara Falls, NY, May 29, 2025 ( GLOBE NEWSWIRE ) -- Positron Corporation ( "Positron" or the "Company" ) POSC, a leader in molecular imaging systems and services, is pleased to announce the sale of its NeuSight PET-CT 64-slice scanner to a prominent nuclear cardiologist specializing in ...
Niagara Falls, NY, April 14, 2025 ( GLOBE NEWSWIRE ) -- Positron Corporation ( "Positron" or the "Company" ) ( OTC: POSC ) , a leading molecular imaging medical device company specializing in PET and PET-CT imaging systems and clinical services, is pleased to announce the sale of four PET-CT ...
